SS&C enters a roughly $1 billion deal to acquire fund network CalaStone
SS&C Technologies Holdings has agreed to acquire Calastone, a global fund network and a technology solution for its wealth and asset management divisions, from investment company Carlyle.
The transaction is valued at approximately £766 million ($1.033 million) due to potential adjustments.
Calastone manages a network that links more than 4,500 financial institutions to 57 markets around the world.
The transaction is scheduled to close in the last quarter of 2025 and is pending regulatory approval.
SS&C expects the transaction to be additional within a year and will use a combination of debt and available cash to raise funds.
Based in offices in London, Luxembourg, Hong Kong, Taipei, Singapore, New York and Sydney, the CalaStone workforce will move to SS&C’s Global Investor & Distribution Solutions Unit.
These employees report to General Manager Nick Wright.
Purchases are consistent with SS&C’s objectives to strengthen investment management and expand its global presence.
Calastone’s network and technical capabilities are said to complement SS&C’s services in fund management, transfer institutions, artificial intelligence and automation.
The integration between the two companies is expected to create a cohesive platform to reduce risk, reduce costs and reduce risk in the global fund ecosystem while supporting recruitment efforts.
This combination is expected to enhance investor services, improve operational efficiency, and enable assets and wealth managers to develop new products and deliver improved results to investors around the world.
“SS&C enters a roughly $1 billion deal to acquire fund network CalaStone” was originally created and published Private Bunker Internationala brand owned by GlobalData.
The information on this site is contained in good faith for general information purposes only. It is not intended to be the advice you should resort to, and we will not give any representations, warranties or warranties, whether express or implied regarding its accuracy or completeness. You should seek expert or expert advice before taking or refraining from taking any medication based on the content on our site.